| Identification | Back Directory | [Name]
Acalabrutinib Metabolite 27 | [CAS]
2230757-47-6 | [Synonyms]
ACP-5862
Acalabrutinib Impurity 1
Acalabrutinib Metabolite 27
Acalabrutinib?active?metabolite?M27
Acalabrutinib Metabolite 27 (ACP-5862)
Acalabrutinib Metabolite 27 (Acalabrutinib Impurity 1)
4-(8-Amino-3-(4-(but-2-ynamido)butanoyl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
4-[8-amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-Benzamide
Benzamide, 4-[8-amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-
Acalabrutinib Metabolite (M27) ACP-5862 D4Q: What is
Acalabrutinib Metabolite (M27) ACP-5862 D4 Q: What is the CAS Number of
Acalabrutinib Metabolite (M27) ACP-5862 D4 | [Molecular Formula]
C26H23N7O3 | [MDL Number]
MFCD32693908 | [MOL File]
2230757-47-6.mol | [Molecular Weight]
481.51 |
| Hazard Information | Back Directory | [Uses]
4-[8-Amino-3-[1-oxo-4-[(1-oxo-2-butyn-1-yl)amino]butyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-benzamide is a metabolite of Acalabrutinib (A115605) which is an experimental anti-cancer drug and a selective Bruton''s tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL). |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
http://www.weikeqi-biotech.com/ |
|